🔎 Trials Near Me

መነሻ › ፎሊኩላር ሊምፎማ › ጆርጂያ

በጆርጂያ ለፎሊኩላር ሊምፎማ የሚደረጉ ክሊኒካዊ ጥናቶች

ለፎሊኩላር ሊምፎማ የሚደረጉ 15 ጥናቶች በጆርጂያ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በጆርጂያ ውስጥ ያሉ ከተሞች

Official study text (English)

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  • Augusta University Medical Center, Augusta
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT07215910

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ ከ0 እስከ 38 · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06131801

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Augusta University, Augusta
  • Southeastern Regional Medical Center, Newnan
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT05006716

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  • Emory University Hospital, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07226843

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

  • Research Site, Atlanta
  • Research Site, Macon
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 130 · ሁሉም ጾታዎች · የተሻሻለው በ21 ሴፕቴ 2026 · NCT06549595

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

  • Piedmont Healthcare, Atlanta
  • Winship Cancer Institute, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ12 እስከ 100 · ሁሉም ጾታዎች · የተሻሻለው በ11 ሴፕቴ 2026 · NCT06784752

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

  • Emory University Hospital/Winship Cancer Institute, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ሴፕቴ 2026 · NCT06860594

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  • Emory University, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦገስ 2026 · NCT05303519

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • Augusta University Medical Center, Augusta
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT05826535

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጁላይ 2026 · NCT03501576

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • Winship Cancer Institute of Emory University, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ጁላይ 2026 · NCT05131022

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Marietta
  • Southeastern Regional Medical Center, Newnan
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ሜይ 2026 · NCT06911502

SynKIR-310 for Relapsed/Refractory B-NHL

  • Winship Cancer Institute of Emory University, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ኤፕሪ 2026 · NCT06544265

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

  • Emory University Hospital/Winship Cancer Institute, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ፌብሩ 2026 · NCT04883437

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Atlanta
  • Massive Bio SYNERGY-AI site, Savannah
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦክቶ 2025 · NCT03452774

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።